Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Biliary Tract & Cholangiocarcinoma

Milind Javle

米林德·贾夫勒

MD

🏢The University of Texas MD Anderson Cancer Center(德克萨斯大学MD安德森癌症中心)🌐USA

Professor, Department of Gastrointestinal Medical Oncology胃肠肿瘤内科学教授

58
h-index
2
Key Papers
2
Awards
2
Key Contributions

👥Biography 个人简介

Milind Javle, MD is a Professor of Gastrointestinal Medical Oncology at MD Anderson Cancer Center and a world-leading authority on biliary tract cancers. He has spearheaded pivotal trials of FGFR2-targeted therapies (pemigatinib, infigratinib) and IDH1 inhibitor ivosidenib in cholangiocarcinoma, fundamentally expanding precision oncology for this underserved malignancy.

Share:

🧪Research Fields 研究领域

Cholangiocarcinoma胆管癌
FGFR2 FusionsFGFR2融合
Pemigatinib培米替尼
Infigratinib英非替尼
IDH1 InhibitorsIDH1抑制剂
Biliary Tract Cancer Targeted Therapy胆道肿瘤靶向治疗

🎓Key Contributions 主要贡献

FGFR2-Targeted Therapy in Cholangiocarcinoma

Conducted seminal trials establishing pemigatinib and infigratinib as effective FGFR2 fusion-targeted agents in intrahepatic cholangiocarcinoma, leading to FDA approvals and setting a new standard for biomarker-driven treatment.

IDH1 Inhibition in Biliary Tract Cancer

Led investigations into ivosidenib for IDH1-mutated cholangiocarcinoma, contributing to approval of the first IDH1-directed therapy in biliary tract cancer and advancing precision oncology in this disease.

Representative Works 代表性著作

[1]

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

The Lancet Oncology (2020)

FIGHT-202 trial demonstrating clinically meaningful responses to pemigatinib in FGFR2 fusion-positive cholangiocarcinoma, leading to FDA approval.

[2]

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations

Journal of Clinical Oncology (2021)

Phase II trial establishing infigratinib efficacy in FGFR2-altered cholangiocarcinoma with durable objective responses.

🏆Awards & Recognition 奖项与荣誉

🏆ASCO Gastrointestinal Cancers Symposium Leadership Award
🏆MD Anderson Faculty Excellence Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 米林德·贾夫勒 的研究动态

Follow Milind Javle's research updates

留下邮箱,当我们发布与 Milind Javle(The University of Texas MD Anderson Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment